BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1803 related articles for article (PubMed ID: 29390873)

  • 1. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
    Siegler EL; Wang P
    Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical pharmacology modeling of chimeric antigen receptor T therapies.
    Kumari R; Ouyang X; Wang J; Xu X; Zheng M; An X; Li QX
    Curr Opin Pharmacol; 2021 Dec; 61():49-61. PubMed ID: 34619442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From antibodies to living drugs: Quo vadis cancer immunotherapy?
    Szöőr Á; Szöllősi J; Vereb G
    Biol Futur; 2021 Mar; 72(1):85-99. PubMed ID: 34554498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
    Han C; Kwon BS
    Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
    Gowrishankar K; Birtwistle L; Micklethwaite K
    Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR-T cell therapy in melanoma: A future success story?
    Simon B; Uslu U
    Exp Dermatol; 2018 Dec; 27(12):1315-1321. PubMed ID: 30288790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
    Ti D; Niu Y; Wu Z; Fu X; Han W
    Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR-T cell and Personalized Medicine.
    Cruz-Ramos M; García-Foncillas J
    Adv Exp Med Biol; 2019; 1168():131-145. PubMed ID: 31713169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead.
    Zhang Q; Ping J; Huang Z; Zhang X; Zhou J; Wang G; Liu S; Ma J
    J Immunol Res; 2020; 2020():1924379. PubMed ID: 32411789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of CAR-T Cells for Cancer Immunotherapy.
    Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
    Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric Antigen Receptor T Cell Immunotherapy for Tumor: A Review of Patent Literatures.
    Fu M; Tang L
    Recent Pat Anticancer Drug Discov; 2019; 14(1):60-69. PubMed ID: 30636615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
    Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
    Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective Targeting of TAG72
    Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
    Front Immunol; 2018; 9():2268. PubMed ID: 30510550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives.
    Lee YH; Kim CH
    Arch Pharm Res; 2019 Jul; 42(7):607-616. PubMed ID: 30830661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor.
    Ma L; Dichwalkar T; Chang JYH; Cossette B; Garafola D; Zhang AQ; Fichter M; Wang C; Liang S; Silva M; Kumari S; Mehta NK; Abraham W; Thai N; Li N; Wittrup KD; Irvine DJ
    Science; 2019 Jul; 365(6449):162-168. PubMed ID: 31296767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 91.